New­path Part­ners kicks off $350M fund with a wun­derkind hold­ing the bag and an all-star sci­en­tif­ic team wait­ing in the wings

The world of biotech isn’t short on big per­son­al­i­ties, but it’s not ex­act­ly com­mon to see young pro­fes­sion­als earn­ing the broad re­spect of sea­soned aca­d­e­mics. Yet, Tom Cahill and his team at New­path have snagged the sup­port of some of biotech’s biggest names in just a few short years in ex­is­tence.

How did Cahill do it? He thinks big.

New­path Part­ners kicked off its sec­ond ven­ture fund Wednes­day, dubbed New­path Fund II, with $350 mil­lion to sup­port re­search from some of the best and bright­est re­searchers and se­r­i­al biotech en­tre­pre­neurs wait­ing in the wings.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN